GlobeNewswire Inc.T3·4mo ago
TRAW Traws Pharma, Inc. Common Stock
XNAS 2.01 DelayedStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
TRAW
$2.01
—
Key stats
$2.01
Pre-market
$0.34
-0.32%
- 52-Week Range
- $0.33 – $3.23
- YTD
- +51.13%
- Straddle Price
- $2.45
- P/C Vol Ratio
- 0.00
- Market Cap
- $0.0B
- Open
- $0.37
- Day Range
- $0.33 – $0.37
- Volume
- 37,543
- Prev Close
- $0.34
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 0.72 |
| Cost of Equity (CAPM) | 8.54% |
| WACC | 8.65% |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | -989.7% |
| Book / Price | -185.0% |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | -711.1% |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $0.51 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $0.45 |
| Bollinger Width / SMA20 | 17293.4% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
Peers used for multiples: ABT, NVS, PFE
(SIC-code peers; ETF co-membership was sector-incoherent)
Blended Fair Value
$0.70
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 39.5× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 19.2× · 3 peers |
| Peer P/B | n/a | 0% | median 3.5× · 3 peers |
| Peer P/S | $1.29 | 24% | median 3.9× · 3 peers |
| Market Anchor (SMA50) | $0.51 | 76% | stability 60% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 7
- List Date
- 2013-07-25
- CIK
- 0001130598
- Next Earnings
- 2026-11-12
- EPS Forecast
- ($0.21) (1 est.)
- Headquarters
- Newtown, PA
- Homepage
- https://www.trawspharma.com
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir m…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '24 | '25 | '26 | Avg |
|---|---|---|---|---|
| Jan | -- | -16.03% | 58.65% | 21.31% |
| Feb | -- | -55.81% | -19.12% | -37.47% |
| Mar | -- | 0.44% | 12.96% | 6.70% |
| Apr | -22.97% | -32.24% | -13.86% | -23.02% |
| May | -13.03% | 0.71% | -2.01% | -4.78% |
| Jun | -25.30% | 4.23% | -42.63% | -21.23% |
| Jul | -8.10% | 5.48% | -47.61% | -16.74% |
| Aug | -3.01% | -4.11% | 25.53% | 6.14% |
| Sep | -35.74% | 28.47% | 0.64% | -2.21% |
| Oct | -9.68% | 35.98% | -37.45%* | -3.72% |
| Nov | -8.23% | 12.97% | -- | 2.37% |
| Dec | 70.77% | -54.44% | -- | 8.16% |
| Total | -59.43% | -75.89% | -70.94% | -68.75% |
* Only 3 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $0.45
SMA 50: $0.51
SMA 200: $1.19
Current: $0.34
EMA 12: $0.39
EMA 26: $0.44
MACD: -0.0515 | Signal: -0.0080
BEARISH
ADX (14): 20.23
WEAK TREND
+DI: 18.78
−DI: 28.96
Momentum Oscillators
RSI (14): 25.76
OVERSOLD
Stoch %K: 4.63
Stoch %D: 5.22
Williams %R: -94.71
Volume & Volatility
BB Upper: $0.62
BB Lower: $0.27
NEUTRAL
OBV: 170,708,447
Vol SMA 20: 177,282
Vol ROC: -78.97%
ATR: $0.04
True Range: $0.04
HV 20: 72.7%
HV 30: 77.3%
HV 60: 78.8%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL (6/10)
Key Drivers and Primary Risks:
- Recent news headlines pointing to positive developments in COVID-19 studies and phase 1 trial completion
- High volatility, indicating potential for significant price movements
- Beta of 1.22 suggests higher risk compared to the broader market
Investment Thesis: Traws Pharma's (TRAW) stock has been affected by market volatility, but recent positive news headlines may indicate a turning point. The company's COVID-19 therapy development and phase 1 trial progress could lead to potential upside.
Recent News Sentiment Impact: Positive sentiment from the last 10 news articles, with themes focusing on clinical trial developments, product updates, and financial results.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): NEUTRAL
- Medium-term (1-3 months): BULLISH
- Long-term (3-12 months): BEARISH
Support/Resistance Levels: Key price levels from moving averages and technical patterns: + SMA 20: $1.93 + SMA 50: $1.93 + SMA 200: $1.89 + Upper Bollinger Band: $2.33
Momentum Signals:
- RSI (14): 40.16 (neutral)
- MACD: Bullish crossover above signal line (-0.03 / Signal: -0.05 / Histogram: 0.02)
Volume Analysis: Volume trends and institutional interest signals: + Volume SMA 20: 85321.86 + OBV: 64462313.92 + Volume Rate of Change: 41.54%
News & Sentiment Analysis
Recent Headlines Summary: Key themes from last 10 news articles focusing on clinical trial developments, product updates, and financial results.
Sentiment Assessment: Positive sentiment with 7 out of 10 headlines having a positive tone.
Catalyst Identification: Upcoming phase 2 COVID-19 study results and potential regulatory approvals.
Market Narrative: Recent news aligns with technical signals, indicating potential upside.
Risk & Volatility Assessment
Beta Interpretation: High risk relative to the broader market (beta: 1.22).
Volatility Regime: Current volatility is higher than historical levels.
Options Market Signals: Low IV rank (0.0%), low expected move ($2.45), and bullish put/call volume ratio (0.00).
Downside Protection: Support levels at SMA 200 ($1.89) and Bollinger Band Lower ($1.53).
Market Context & Positioning
Sector Performance: Traws Pharma's sector is performing relatively strong.
Institutional Activity: Volume patterns suggesting institutional interest in the stock.
Correlation Analysis: Stock moves more than the market (R-squared: 0.19).
Relative Valuation: Position within trading range, with potential for upside if news catalysts materialize.
Key Levels & Action Items
Critical Price Levels: SMA 20 ($1.93), SMA 50 ($1.93), and Upper Bollinger Band ($2.33) serve as key support and resistance levels.
Breakout/Breakdown Levels: Break above $2.33 or below $1.53 could trigger significant price movements.
Time-Sensitive Catalysts: Phase 2 COVID-19 study results and potential regulatory approvals.
Risk Management: Consider stop-loss levels at SMA 200 ($1.89) and position sizing based on volatility expectations.
Confidence Level: 6/10 (based on data quality, signal clarity, and market context)
Please note that this is a simulated analysis report and should not be taken as personalized investment advice.
Generated
News
All TRAW news →
GlobeNewswire Inc.T3·12mo ago
GlobeNewswire Inc.T3·14mo ago
GlobeNewswire Inc.T3·17mo ago
GlobeNewswire Inc.T3·29mo ago
Zacks Investment ResearchT3·30mo ago
GlobeNewswire Inc.T3·30mo ago
BenzingaT3·31mo ago
Earnings History
3 of 3 under expected move
Avg Expected Move
319.92%
Avg Actual Move
8.08%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-08-15 | unknown | 760.58% | 6.69% | 0.01x | Within |
| 2024-11-14 | unknown | 90.49% | 10.59% | 0.12x | Within |
| 2025-03-31 | unknown | 108.70% | 6.96% | 0.06x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
TRAW Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: $2.45
7-DTE Move: $2.45
Days to Exp: — (2025-04-17)
Options Flow
Call Volume: 2
Put Volume: 0
P/C Volume: —
BULLISH
Call OI: 326
Put OI: 0
P/C OI: —
Total OI: 326
ATM Options Pricing
ATM Call: $0.03
ATM Put: $2.42
Call %: 1.2%
Put %: 120.6%
Chain Summary
Chain Volume: 2
Chain OI: 326
Last Updated: 4/17/2025
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Apr 15 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Apr 15 · No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$2.45Apr 17
Beta Analysis
Risk Metrics
Beta: 1.4770
Alpha: -143.47%
Correlation: 0.1491
R-Squared: 2.2%
Stock Volatility: 126.2%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
TRAW Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 8,414,191 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
TRAW Insider Trading (Form 4)
Latest: 2026-07-16Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-07-16 | Charles David Pauza | Chief Science Officer Virology | Grant (A) | +97,000 opt | — | EDGAR | |
| 2026-07-15 | Werner Cautreels | Director | Grant (A) | +14,150 opt | — | EDGAR | |
| 2026-07-15 | Nikolay Savchuk | Chief Operating Officer | Grant (A) | +93,000 opt | — | EDGAR | |
| 2026-07-14 | Charles Nolan Parker | Chief Financial Officer | Grant (A) | +90,000 opt | — | EDGAR | |
| 2026-07-14 | Robert Redfield | Chief Medical Officer | Grant (A) | +84,000 opt | — | EDGAR | |
| 2026-07-14 | Mary Teresa Shoemaker | Director | Grant (A) | +14,150 opt | — | EDGAR | |
| 2026-07-14 | John Harold Leaman | Director | Grant (A) | +14,150 opt | — | EDGAR | |
| 2026-07-14 | Iain D. Dukes | Chief Executive Officer | Grant (A) | +274,000 opt | — | EDGAR | |
| 2026-07-14 | Jack E Stover | Director | Grant (A) | +14,150 opt | — | EDGAR | |
| 2026-07-14 | Trafford Clarke | Director | Grant (A) | +14,150 opt | — | EDGAR | |
| 2026-04-28 | OrbiMed Capital GP VIII LLC | 10%+ Owner | Buy (P) | +1,195,458 | $1.67 | $2.00M | EDGAR |
| 2026-04-08 | Charles Nolan Parker | Chief Financial Officer | Award (A) | +15,393 | — | EDGAR | |
| 2026-03-10 | Jack E Stover | Director | Grant (A) | +33,435 opt | — | EDGAR | |
| 2026-03-10 | Iain D. Dukes | Chief Executive Officer | Grant (A) | +231,336 opt | — | EDGAR | |
| 2026-03-10 | Werner Cautreels | Director | Grant (A) | +31,258 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
TRAW Insider Holdings
11 insiders · @ $0.34
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | OrbiMed Capital GP VIII LLC | 10%+ Owner | 1,203,250 | $410.4K | $2.00M | 2 | 2026-04-28 |
| 2 | Iain D. Dukes | Chief Executive Officer | 236,934 | $80.8K | $0 | 6 | 2026-07-14 |
| 3 | Nikolay Savchuk | Chief Operating Officer | 216,410 | $73.8K | $0 | 7 | 2026-07-15 |
| 4 | Charles David Pauza | Chief Science Officer Virology | 115,971 | $39.6K | $0 | 5 | 2026-07-16 |
| 5 | Robert Redfield | Chief Medical Officer | 113,919 | $38.9K | $0 | 5 | 2026-07-14 |
| 6 | Werner Cautreels | Director | 109,222 | $37.3K | $0 | 8 | 2026-07-15 |
| 7 | Charles Nolan Parker | Chief Financial Officer | 15,393 | $5.3K | $0 | 2 | 2026-07-14 |
| 8 | Mary Teresa Shoemaker | Director | 6,292 | $2.1K | $0 | 5 | 2026-07-14 |
| 9 | Jack E Stover | Director | 6,165 | $2.1K | $0 | 5 | 2026-07-14 |
| 10 | Trafford Clarke | Director | 6,157 | $2.1K | $0 | 5 | 2026-07-14 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
TRAW Board & Officers
As of SEC filings through Jul 16, 2026Directors 7
- Jack E Stover · since May 18, 2016
- Mary Teresa Shoemaker · since May 27, 2020
- Trafford Clarke · since Dec 15, 2022
- Iain D. Dukes · since Apr 1, 2024
- Werner Cautreels · since Apr 1, 2024
- John Harold Leaman · since Oct 1, 2025
- Nikolay Savchuk · listed since Mar 2026
Officers 5
- Iain D. Dukes · Chief Executive Officer · listed since Oct 2025
- Charles Nolan Parker · Chief Financial Officer · since Jul 3, 2025
- Nikolay Savchuk · Chief Operating Officer · listed since Mar 2026
- Charles David Pauza · Chief Science Officer Virology · since Apr 1, 2024
- Robert Redfield · Chief Medical Officer · listed since Oct 2025
10% owners 2
- OrbiMed Capital GP VIII LLC (entity) · since Apr 1, 2024
- Orbimed Advisors LLC (entity) · since Apr 1, 2024
Changes in the last 10 years (59)
| Mar 10, 2026 | Nikolay Savchuk first listed as a director in an SEC filing |
| Mar 10, 2026 | Nikolay Savchuk first listed as Chief Operating Officer in an SEC filing |
| Oct 15, 2025 | Robert Redfield listed as Chief Medical Officer (previously Acting Chief Medical Officer) in SEC filings |
| Oct 15, 2025 | Iain D. Dukes listed as Chief Executive Officer (previously Executive Chairman) in SEC filings |
| Oct 1, 2025 | John Harold Leaman became a director |
| Jul 3, 2025 | Charles Nolan Parker became Chief Financial Officer |
| Jul 2, 2025 | The company announced the departure of Nora Brennan as Interim CFO in an SEC filing |
| Apr 8, 2025 | Tpav, LLC reported in an SEC filing no longer being a 10% owner |
| Apr 8, 2025 | Nikolay Savchuk reported in an SEC filing no longer being a director |
| Apr 8, 2025 | Nikolay Savchuk reported in an SEC filing no longer being a 10% owner |
| Apr 8, 2025 | Nikolay Savchuk reported in an SEC filing no longer being Chief Operating Officer |
| Feb 5, 2025 | Nora Brennan became Interim CFO |
| Feb 5, 2025 | Mark Patrick Guerin left as CFO and COO, per their own SEC filing |
| Jan 27, 2025 | Nikolay Savchuk first listed as a 10% owner in an SEC filing |
| Dec 16, 2024 | The company announced the departure of Luba Greenwood from the board in an SEC filing |
| Sep 16, 2024 | The company announced the departure of James J Marino from the board in an SEC filing |
| Sep 16, 2024 | Luba Greenwood became a director |
| Jun 17, 2024 | The company announced the departure of Steven M Fruchtman as President, Chief Executive Off in an SEC filing |
| Apr 3, 2024 | Viriom, Inc. became a 10% owner |
| Apr 1, 2024 | Werner Cautreels became a director |
| Apr 1, 2024 | Werner Cautreels became Chief Executive Officer |
| Apr 1, 2024 | Tpav, LLC became a 10% owner |
| Apr 1, 2024 | The company announced the departure of Werner Cautreels as Chief Executive Officer in an SEC filing |
| Apr 1, 2024 | Robert Redfield became Acting Chief Medical Officer |
| Apr 1, 2024 | Orbimed Advisors LLC became a 10% owner |
| Apr 1, 2024 | OrbiMed Capital GP VIII LLC became a 10% owner |
| Apr 1, 2024 | Nikolay Savchuk became a director |
| Apr 1, 2024 | Nikolay Savchuk became Chief Operating Officer |
| Apr 1, 2024 | Iain D. Dukes became a director |
| Apr 1, 2024 | Iain D. Dukes became Executive Chairman |
| Apr 1, 2024 | Charles David Pauza became Chief Science Officer Virology |
| Oct 2, 2023 | Victor M Moyo became Chief Medical Officer |
| Dec 15, 2022 | Trafford Clarke became a director |
| Dec 15, 2022 | Peter Atadja became a director |
| Jun 13, 2022 | Mark Patrick Guerin listed as CFO and COO (previously Chief Financial Officer) in SEC filings |
| Jun 10, 2022 | The company announced the departure of Abraham N. Oler as SVP Corp Dev & Gen Counsel in an SEC filing |
| Jun 14, 2021 | Mark S. MD Gelder became Chief Medical Officer |
| Aug 31, 2020 | Michael B Hoffman reported in an SEC filing no longer being a director |
| Aug 31, 2020 | E Premkumar Reddy reported in an SEC filing no longer being a director |
| May 27, 2020 | Mary Teresa Shoemaker became a director |
| May 20, 2020 | Abraham N. Oler listed as SVP Corp Dev & Gen Counsel (previously VP Corp Dev & Gen Counsel) in SEC filings |
| Nov 26, 2019 | Steven M Fruchtman listed as President, Chief Executive Off (previously Chief Medical Officer) in SEC filings |
| Nov 26, 2019 | Steven M Fruchtman first listed as a director in an SEC filing |
| Sep 26, 2019 | Tyndall Capital Partners L P reported in an SEC filing no longer being a 10% owner |
| Sep 25, 2019 | Steven Boyd reported in an SEC filing no longer being a 10% owner |
| Sep 25, 2019 | Armistice Capital, LLC reported in an SEC filing no longer being a 10% owner |
| Sep 25, 2019 | Armistice Capital Master Fund Ltd. reported in an SEC filing no longer being a 10% owner |
| Sep 23, 2019 | Steven Boyd became a 10% owner |
| Sep 23, 2019 | Armistice Capital, LLC became a 10% owner |
| Sep 23, 2019 | Armistice Capital Master Fund Ltd. became a 10% owner |
| Sep 20, 2019 | Ari Zweiman reported in an SEC filing no longer being a 10% owner |
| Sep 20, 2019 | 683 Capital Partners, LP reported in an SEC filing no longer being a 10% owner |
| Sep 20, 2019 | 683 Capital Management, LLC reported in an SEC filing no longer being a 10% owner |
| Dec 12, 2018 | Abraham N. Oler became VP Corp Dev & Gen Counsel |
| Nov 5, 2018 | Richard Charles Woodman became Chief Medical Officer |
| May 1, 2018 | Michael B Hoffman no longer listed as a 10% owner in SEC filings |
| May 1, 2018 | Ari Zweiman became a 10% owner |
| Feb 8, 2018 | 683 Capital Partners, LP became a 10% owner |
| Feb 8, 2018 | 683 Capital Management, LLC became a 10% owner |
Not reported recently (11)
- Viriom, Inc. · Last reported as a 10% owner in an SEC filing dated Apr 3, 2024
- Steven M Fruchtman · Last reported as a director in an SEC filing dated Mar 15, 2024
- Victor M Moyo · Last reported as Chief Medical Officer in an SEC filing dated Oct 27, 2023
- Jerome Groopman · Last reported as a director in an SEC filing dated Aug 14, 2023
- Viren Mehta · Last reported as a director in an SEC filing dated Aug 14, 2023
- Peter Atadja · Last reported as a director in an SEC filing dated Aug 14, 2023
- Mark S. MD Gelder · Last reported as Chief Medical Officer in an SEC filing dated Mar 14, 2023
- Manoj Maniar · Last reported as SVP - Product Development in an SEC filing dated Jul 10, 2020
- Richard Charles Woodman · Last reported as Chief Medical Officer in an SEC filing dated Jul 10, 2020
- Ramesh Kumar · Last reported as a director in an SEC filing dated Jul 30, 2018
- Henry S Bienen · Last reported as a director in an SEC filing dated May 31, 2018
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
TRAW Proposed Insider Sales (Form 144)
Latest: 2024-03-14
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2024-03-14 | MARK GUERIN | Officer | 2,591 | $2.3K | 2024-03-14 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2024-03-14 | STEVEN M FRUCHTMAN | Officer, Director | 8,727 | $7.9K | 2024-03-14 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2024-02-08 | STEVEN M FRUCHTMAN | Officer, Director | 9,212 | $6.2K | 2024-02-08 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
1 ETF hold TRAW
1 shown · $90.76K total exposure
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $90,762 | — | 2026-09-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-1.69
TTM Revenue
$2.73M
TTM Net Income
$-14.75M
TTM Op. Cash Flow
$-15.32M
Quarterly figures (8 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '26 | 2026-03-31 | — | $-5.69M | $-0.53 | $-2.58M |
| Q4 '25 | 2025-12-31 | $0.00 | $-5.40M | $-0.71 | $-2.76M |
| Q3 '25 | 2025-09-30 | — | $-3.04M | $-0.34 | $-4.01M |
| Q2 '25 | 2025-06-30 | $2.73M | $-625.00K | $-0.11 | $-5.98M |
| Q1 '25 | 2025-03-31 | $57.00K | $15.08M | $2.09 | $-5.44M |
| Q4 '24 | 2024-12-31 | $56.00K | $-21.42M | $-3.35 | $-4.04M |
| Q3 '24 | 2024-09-30 | $57.00K | $-1.43M | $-1.49 | $-11.48M |
| Q2 '24 | 2024-06-30 | $57.00K | $-20.77M | $-20.52 | $-9.85M |
Q1 2026 • period ending 2026-03-31 • filed 2026-05-15
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
—
P/S
1.05
EV/EBITDA
—
EV/Sales
-0.10
ROE
—
ROA
-180.8%
Div Yield
0.00%
FCF Yield
-533.92%
Debt/Equity
—
Current Ratio
—
Market Cap
$2.87M
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
690.68K
SI % of Float
5.22%
Days to Cover
1.00
Short Vol Ratio
39.0%
Free Float
13.23M
Float %
86.1%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-09-30